Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials.
Ishida S, Chen SJ, Murata T, Ogura Y, Ruamviboonsuk P, Sakamoto T, Fujita T, Kawano M, Ohsawa S, Abreu F, Haskova Z, Ives J, Silverman D, Yoon YH; YOSEMITE and RHINE Investigators. Ishida S, et al. Among authors: ohsawa s. Asia Pac J Ophthalmol (Phila). 2023 Sep-Oct 01;12(5):451-459. doi: 10.1097/APO.0000000000000634. Epub 2023 Sep 22. Asia Pac J Ophthalmol (Phila). 2023. PMID: 37851562 Free article. Clinical Trial.
Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.
Takahashi K, Cheung CMG, Iida T, Lai TYY, Ohji M, Yanagi Y, Kawano M, Ohsawa S, Suzuki T, Kotecha A, Lin H, Patel V, Swaminathan B, Lee WK; TENAYA, LUCERNE Investigators. Takahashi K, et al. Among authors: ohsawa s. Graefes Arch Clin Exp Ophthalmol. 2023 Nov;261(11):3125-3137. doi: 10.1007/s00417-023-06071-8. Epub 2023 Jun 9. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 37294433 Free PMC article.
Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
Mori R, Honda S, Gomi F, Tsujikawa A, Koizumi H, Ochi H, Ohsawa S, Okada AA; TENAYA and LUCERNE Investigators. Mori R, et al. Among authors: ohsawa s. Jpn J Ophthalmol. 2023 May;67(3):311. doi: 10.1007/s10384-023-00996-7. Jpn J Ophthalmol. 2023. PMID: 37154984 Free PMC article. No abstract available.
151 results